Trials / Terminated
TerminatedNCT04501952
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 584 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDV | Administered as an intravenous infusion |
| DRUG | Placebo to Match RDV | Administered as an intravenous infusion |
Timeline
- Start date
- 2020-09-18
- Primary completion
- 2021-05-06
- Completion
- 2021-05-06
- First posted
- 2020-08-06
- Last updated
- 2021-11-16
- Results posted
- 2021-11-16
Locations
104 sites across 4 countries: United States, Denmark, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04501952. Inclusion in this directory is not an endorsement.